Petaluma, Calif. • (707) 283-0550 • www.oculusis.com
Exchange and Ticker. Nasdaq: OCLS
Filing Range: 3.08M shares @ $12.00 to $14.00
Offering Price: $8.00
Close on First Day: $7.80
Offering Size: $24.20M
Shares Outstanding: 11,424,209 M
Underwriters: Roth Capital Partners Inc.
Co-managers: Brookstreet Securities/ Maxim Group LLC
Company Counsel: Pillsbury Winthrop Shaw Pitt LLP
Manager Counsel: Stradling Yocca Carlson & Rauth
Auditor: Marcum & Kliegman LLP
Market Capitalization on 1/31/07: $89.11M
Closing price on 1/31/07: $7.67
The company develops, manufactures and markets a family of products intended to prevent and eliminate infection in chronic and acute wounds. Oculus’ platform technology, called Microcyn, is a non-toxic, super-oxidized water-based solution that is designed to eliminate a wide range of pathogens, including viruses, fungi, spores and antibiotic-resistant strains of bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococcus (VRE). The company’s competitors include Kinetic Concepts Inc., Integra Life Sciences, Life Cell, Organogenesis, Ortec International, Celleration and PuriCore. Oculus was formerly known as Micromed Laboratories.
Western Technology Investment, individuals and undisclosed venture and non-venture investors.
Source: Thomson Financial